Frost & Sullivan releases 'Global and China Antibiotic Market Research'

In 2020, the outbreak and spread of COVID-19 posed a serious threat to human life safety and health. The novel coronavirus, characterized by high infectivity, leads to viral pneumonia, while 10-30% of influenza virus patients develop secondary bacterial infections. A retrospective study published in the journal The Lancet indicates that about half of the COVID-19 patients who died from infection had secondary bacterial infections, leading to sepsis and death. Therefore, focusing on the pathogenic mechanisms of pathogens and microbial resistance, as well as rapidly controlling the occurrence and development of related hazards, has become one of the key research areas in the pharmaceutical industry. For this reason, based on research into this market, Frost & Sullivan (Frost & Sullivan) has released a relevant industry report.